Welcome to our dedicated page for Ascentage Pharma Group International news (Ticker: AAPG), a resource for investors and traders seeking the latest updates and insights on Ascentage Pharma Group International stock.
Ascentage Pharma Group International reports recurring developments in cancer-focused drug commercialization and clinical development. The company is a global, commercial-stage integrated biopharmaceutical issuer with American depositary shares on Nasdaq and ordinary shares listed on HKEX. Its updates center on Olverembatinib, a third-generation BCR-ABL inhibitor approved in China, and Lisaftoclax, a China-developed Bcl-2 selective inhibitor, as well as oncology candidates such as Alrizomadlin, APG-2449, APG-5918 and APG-3288.
News from AAPG also covers clinical and preclinical data presented at oncology meetings, regulatory clearances for investigational studies, full-year financial results, commercial activity in China, pipeline progress in hematologic malignancies and solid tumors, and investor-conference communications.
Ascentage Pharma (Nasdaq: AAPG) has successfully completed its U.S. initial public offering, raising approximately $126.4 million in gross proceeds. The company offered 7,325,000 American depositary shares (ADSs) at $17.25 per ADS, with each ADS representing four ordinary shares. Trading of the ADSs commenced on the Nasdaq Global Market on January 24, 2025.
The company has granted underwriters a 30-day option to purchase up to an additional 1,098,750 ADSs at the initial offering price, less underwriting discounts and commissions. J.P. Morgan and Citigroup served as joint book-running managers for the offering.